Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive immuno-oncology combination study in advanced renal cell carcinoma
MOH_2017-05-15_000373Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab, ipilimumab, relatlimab, linrodostat and BMS-813160 in renal cell carcinoma (RCC) (5 arms), sponsored by Bristol Myers Squibb. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2017-05-15_000373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-15_000373.